Atossa Therapeutics Inc (ATOS)

Oct 11, 2025

Can a trend reversal in Atossa Therapeutics Inc. lead to recoveryEarnings Growth Report & Stepwise Swing Trade Plans - newser.com

Oct 11, 2025

Oct 10, 2025

Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pueblo Chieftain

Oct 10, 2025

Oct 10, 2025

Is Atossa Therapeutics Inc. stock ready for a breakoutJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

How to forecast Atossa Therapeutics Inc. trends using time seriesGap Down & Weekly Market Pulse Updates - newser.com

Oct 10, 2025

Oct 10, 2025

Is Atossa Therapeutics Inc. stock entering bullish territoryMarket Growth Report & Fast Moving Stock Trade Plans - newser.com

Oct 10, 2025

Oct 10, 2025

Comparing Atossa Therapeutics Inc. in custom built stock radars2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com

Oct 10, 2025

Oct 10, 2025

Published on: 2025-10-10 02:05:17 - newser.com

Oct 10, 2025

Oct 09, 2025

Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS) - MarketBeat

Oct 09, 2025

Oct 09, 2025

Can Atossa Therapeutics Inc. (YAG2) stock deliver double digit returnsOptions Play & Weekly Breakout Watchlists - newser.com

Oct 09, 2025

Oct 09, 2025

Signal strength of Atossa Therapeutics Inc. stock in tech scannersTrade Entry Report & Weekly Momentum Picks - newser.com

Oct 09, 2025

Oct 09, 2025

Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price targetQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com

Oct 09, 2025

Oct 07, 2025

Atossa Therapeutics (ATOS) Announces Upcoming Virtual Meeting - GuruFocus

Oct 07, 2025

Oct 06, 2025

Atossa streamlines breast cancer trial to focus on 2026 NDA plans - Investing.com

Oct 06, 2025

Oct 06, 2025

Atossa Therapeutics streamlines Evangeline breast cancer clinical trial to prioritize for 2026 NDA-enabling activities - MarketScreener

Oct 06, 2025

Oct 06, 2025

40–65-Patient EVANGELINE Redesign: Atossa Prioritizes 2026 NDA‑Enabling Activities, Reduces Study Costs - Stock Titan

Oct 06, 2025

Oct 06, 2025

Can Atossa Therapeutics Inc. (YAG2) stock stage a strong rebound this quarter2025 Trading Recap & Intraday High Probability Alerts - newser.com

Oct 06, 2025

Oct 06, 2025

Atossa Therapeutics Inc. stock retracement – recovery analysisEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com

Oct 06, 2025

Oct 06, 2025

Can Atossa Therapeutics Inc. stock hit analyst price targetsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com

Oct 06, 2025

Oct 02, 2025

Atossa Therapeutics appoints Janet Rea as SVP of R&D By Investing.com - Investing.com Nigeria

Oct 02, 2025

Oct 01, 2025

Atossa Therapeutics appoints Janet Rea as SVP of R&D - Investing.com

Oct 01, 2025

Oct 01, 2025

What drives Atossa Therapeutics Inc YAG2 stock priceDouble Top/Bottom Patterns & Superior Trading Ideas - earlytimes.in

Oct 01, 2025

Oct 01, 2025

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones - StreetInsider

Oct 01, 2025

Oct 01, 2025

Veteran Drug Approval Expert Returns to Atossa Therapeutics to Advance Breakthrough Breast Cancer Treatment - Stock Titan

Oct 01, 2025

Sep 30, 2025

Goldman Sachs Group Inc. Lowers Holdings in Atossa Genetics Inc. $ATOS - Defense World

Sep 30, 2025

Sep 29, 2025

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian

Sep 29, 2025

Sep 28, 2025

What analysts say about Atossa Therapeutics Inc stockSector-Based Investing & Build Capital Safely - earlytimes.in

Sep 28, 2025